2024
Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategies
2010
Optimizing statin treatment for primary prevention of coronary artery disease.
Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Annals Of Internal Medicine 2010, 152: 69-77. PMID: 20083825, DOI: 10.7326/0003-4819-152-2-201001190-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCholesterol, LDLClinical Trials as TopicComputer SimulationCoronary Artery DiseaseDrug Administration ScheduleFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrimary PreventionQuality-Adjusted Life YearsRisk FactorsSensitivity and SpecificityTreatment OutcomeConceptsHigh-dose statinsQuality Enhancement Research InitiativeStatin therapyMore QALYsNational Cholesterol Education Program III guidelinesTreatment approachesCoronary artery disease preventionVeterans Affairs Health Services ResearchDoses of statinsCoronary artery diseaseRisk factor dataAvailable clinical dataYears of treatmentTarget approachBase-case analysisHealth services researchPersons 75 yearsStatin doseStatin trialsCAD eventsStatin treatmentArtery diseaseCAD riskPrimary preventionMyocardial infarction